Market Research Report
Microbiome Therapeutics: Global Markets
|Published by||BCC Research||Product code||963472|
|Published||Content info||167 Pages
Delivery time: 1-2 business days
|Microbiome Therapeutics: Global Markets|
|Published: October 6, 2020||Content info: 167 Pages||
The global market for microbiome therapeutics should grow from $141.7 million in 2021 to $1.3 billion by 2026, at compound annual growth rate (CAGR) of 56.4% for the period of 2021-2026.
GIT diseases market for microbiome therapeutics should grow from $87.9 million in 2021 to $222.0 million by 2026, at a CAGR of 20.4% for the period of 2021-2026.
Infections diseases market for microbiome therapeutics should grow from $53.8 million in 2021 to $191.8 million by 2026, at a CAGR of 28.9% for the period of 2021-2026.
BCC Research's new report, "Microbiome Therapeutics: Global Markets," provides a comprehensive analysis of the microbiome therapeutics market in global context, including market forecasts and sales through 2025. The report analyzes the market by segmenting it into the various types of microbiome therapeutics, based on the strategies used for treatment: additive (fecal matter transplants or FMTs, live biotherapeutic products or LBPs), modulatory (postbiotics, prebiotics) and subtractive microbiome therapeutics (phages and antimicrobials). This study surveys the microbiome therapeutics market by application or disease segments: infectious diseases, metabolic diseases, cancer, gut-brain axis and others. The market is also assessed in the following geographic regions: North America, Europe and emerging markets. Emerging markets include countries like India, China, Korea, Taiwan, Africa, Australia, New Zealand, Canada and Latin America.
The report features leading clinical trials indicating the status and phase of development. New developments and patents are boosting the growth of this market in the global context.
The new BCC report provides comprehensive profiles of market players in the industry. The industry structure chapter focuses on the changing market trends, market players and their leading pipeline candidates. This chapter also covers the mergers and acquisitions and any other collaborations or partnerships that happened during the evaluation period of this report that are expected to shape the industry.
Factors such as strengths, weaknesses, threats and opportunities that are expected to play a role in the microbiome therapeutics market are evaluated in detail.
Excluded from this report are the markets for prebiotics and probiotics labeled as nutritional or dietary supplements. Prebiotics and probiotics, if included, only pertain to when used in the context of microbiome therapy.